Application
ARHGEF1 Antibody (N-term) western blot analysis in CEM cell line lysates (35ug/lane).This demonstrates the ARHGEF1 antibody detected the ARHGEF1 protein (arrow).| Product Name | ARHGEF1 Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | ARHGEF1; Rho guanine nucleotide exchange factor 1; 115 kDa guanine nucleotide exchange factor; Sub1.5 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | ARHGEF1 Rho guanine nucleotide exchange factor 1 115 kDa guanine nucleotide exchange factor Sub1.5 |
|---|---|
| Molecular Weight(MW) | 102435 Da |
| Function | Seems to play a role in the regulation of RhoA GTPase by guanine nucleotide-binding alpha-12 (GNA12) and alpha-13 (GNA13) subunits. Acts as GTPase-activating protein (GAP) for GNA12 and GNA13, and as guanine nucleotide exchange factor (GEF) for RhoA GTPase. Activated G alpha 13/GNA13 stimulates the RhoGEF activity through interaction with the RGS-like domain. This GEF activity is inhibited by binding to activated GNA12. Mediates angiotensin-2- induced RhoA activation |
| Tissue Specificity | Ubiquitously expressed. |
| Cellular Localization | Cytoplasm. Membrane. Note=Translocated to the membrane by activated GNA13 or LPA stimulation |
| Entrez Gene | 9138 |
|---|---|
| Nucleotide Accession | NP_945328.1 NP_945353.1 NP_004697.2 |
Application
ARHGEF1 Antibody (N-term) western blot analysis in CEM cell line lysates (35ug/lane).This demonstrates the ARHGEF1 antibody detected the ARHGEF1 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
